BiotechTube

MK-8510

Phase 1Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV-1

Conditions

HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1

Trial Timeline

Apr 17, 2023 → Feb 14, 2024

NCT ID
NCT05700734

About MK-8510

MK-8510 is a phase 1 stage product being developed by Merck for HIV-1. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05700734. Target conditions include HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human.

What happened to similar drugs?

20 of 20 similar drugs in HIV-1 were approved

Approved (20) Terminated (2) Active (0)
✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
✅B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboGilead SciencesApproved
✅B/F/TAFGilead SciencesApproved
✅STB + TVD + ATR + RTV + ATV + ABC/3TC + IohexolGilead SciencesApproved
✅Genvoya + Epclusa + BiktarvyGilead SciencesApproved
✅TruvadaGilead SciencesApproved
✅Truvada + Kaletra + Kivexa + KaletraGilead SciencesApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05700734Phase 1Withdrawn

Competing Products

20 competing products in HIV-1

See all competitors
ProductCompanyStageHype Score
DOR/ISLMerckPhase 2
35
SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；PlaceboJiangsu Hengrui MedicinePhase 1
29
Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved
43
lopinavir/ritonavir + lamivudineAbbViePre-clinical
26
CVC 150 mg + CVC 300 mgAbbViePhase 2
35
Doravirine, Tenofovir, Lamivudine - Blinded + Doravirine, Tenofovir, Lamivudine - Open-Label + ATRIPLA^TM + Placebo to ATRIPLA™ + Placebo to Doravirine, Tenofovir, LamivudineMerckPhase 2
35
DOR/ISL + BIC/FTC/TAF + Placebo to BIC/FTC/TAF + Placebo to DOR/ISLMerckPhase 3
40
VorinostatMerckPhase 1/2
32
IslatravirMerckPhase 1
29
Doravirine, Tenofovir, Lamivudine + Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor + Baseline regimen of cobicistat-boosted elvitegravir + Baseline regimen of a non-nucleoside reverse transcriptase inhibitor + Baseline regimen of two nucleoside reverse transcriptase inhibitorsMerckPhase 3
40
raltegravir and etravirineMerckPhase 2
35
Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)MerckPhase 1
29
ISL + ULO + BIC/FTC/TAFMerckPhase 2
39
UlonivirineMerckPhase 1
29
Islatravir + Placebo to Islatravir + Doravirine + Placebo to Doravirine + Lamivudine + Placebo to Lamivudine + Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Doravirine/IslatravirMerckPhase 2
35
MK0518 (Raltegravir) + famotidine + omeprazoleMerckPhase 1
29
DoravirineMerckPhase 1
29
18F-RaltegravirMerckPhase 1
36
Pegylated Interferon alpha 2bMerckPhase 2
35
MK-8583MerckPhase 1
29